Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: A biostimulator includes a housing having a longitudinal axis and containing an electronics compartment. A pacing element is coupled to the housing. The pacing element includes a flexible conductor extending along the longitudinal axis. A fixation element mount is mounted on the housing. The fixation element mount includes a distal mount end. A fixation element is mounted on the fixation element mount. The fixation element extends about the longitudinal axis. A radiopaque marker has a distal marker end longitudinally aligned with the distal mount end of the fixation element mount. Other embodiments are also described and claimed.

Abstract: A biostimulator includes a housing having a longitudinal axis and containing an electronics compartment. The biostimulator includes a fixation element coupled to the housing. The fixation element extends about the longitudinal axis. The biostimulator includes a pacing element coupled to the housing. The pacing element includes a flexible conductor extending along the longitudinal axis and a stiffening strand extending beside the flexible conductor. A bending stiffness of the stiffening strand is greater than a bending stiffness of the flexible conductor. Other embodiments are also described and claimed.

Abstract: A biostimulator includes a housing, a fixation element, and a probe. The housing includes an electronics compartment containing circuitry. The fixation element is coupled to the housing. The probe is coupled to the housing and electrically connected to the circuitry. The probe includes a flexible body extending to a tip. The flexible body includes a conductive layer laminated on a substrate layer. Other embodiments are also described and claimed.

Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, A-III, A-IV, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: A biostimulator includes a housing having a longitudinal axis and containing an electronics compartment. The biostimulator includes a fixation element coupled to the housing. The fixation element extends about the longitudinal axis. The biostimulator includes a pacing element coupled to the housing. The pacing element includes a strain relief surrounding a flexible conductor distal to the fixation element. A stiffness of the strain relief decreases in a distal direction. Other embodiments are also described and claimed.

Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Abstract: A biostimulator and a biostimulator system for septal pacing, is described. The biostimulator includes a joint to allow an electrode to pivot relative to a housing. The housing contains electrical circuitry that is electrically connected to the pacing electrode. The joint allows the pacing electrode to affix to target tissue of an interventricular septal wall of a heart when the housing is pivoted toward an apex of the heart. Other embodiments are also described and claimed.

Abstract: This application relates to compounds of Formula (I): [targeting peptide]-N(R1)—X1(R2)L1-[linker]-RXn1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr). R1 is H or methyl. X1 is an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms. R2 is C(O)OH or C(O)NH2. L1 is a linkage (thiolether, amide, maleimide-thiol, triazole). The linker has a net negative charge at physiological pH and is a linear or branched chain of 1-10 units of X2L2 and/or X2(L2)2, wherein: each X2 is, independently, an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms; and each L2 is a linkage. The linker optionally further comprises an albumin binder bonded to an L2. Each RX is a radiolabelling group linked through a separate L2, selected from: a metal chelator; a prosthetic group containing trifluoroborate (BF3); or a prosthetic group containing a silicon-fluorine-acceptor moiety.